Carisma Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 86.88 million compared to USD 61.23 million a year ago. Basic loss per share from continuing operations was USD 2.59 compared to USD 28.77 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.67 USD | +1.83% | -10.70% | -43.00% |
Apr. 11 | BTIG Starts Carisma Therapeutics With Buy Rating, $6 Price Target | MT |
Apr. 02 | HC Wainwright Adjusts Price Target on Carisma Therapeutics to $9 From $11, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-43.00% | 68.13M | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- CARM Stock
- News Carisma Therapeutics, Inc.
- Carisma Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023